在严重的SARS-CoV-2感染和短期死亡率中使用的不同皮质类固醇疗法之间的关联:回顾性队列研究
A González-Castro1, A Fernandez1, E Cuenca-Fito1
1Servicio de Medicina Intensiva, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain.
Revista espanola de anestesiologia y reanimacion
|February 23, 2024
概括
这项研究发现,每天服用6mg德克萨米他可能会降低重症COVID-19患者的28天死亡率. 皮质类固醇治疗,包括甲基普雷迪尼索隆,在严重的SARS-CoV-2感染中显示出除了单独使用德甲之外的好处.
科学领域:
- 关键护理医学 关键护理医学
- 传染性疾病 传染性疾病
- 药理学 药理学是指药理学的学科.
背景情况:
- 皮质类固醇治疗方案在治疗SARS-CoV-2感染方面表现出不同的疗效.
- 了解特定的皮质类固醇治疗方案对死亡率的影响对于重症患者至关重要.
研究的目的:
- 分析与SARS-CoV-2感染的ICU患者中德克萨米他和甲基前尼索隆治疗方案相关的早期死亡率的差异.
- 为了评估不同类型的皮质类固醇治疗对28天死亡率的有效性.
主要方法:
- 对539名已成年患者进行了回顾性观察性研究,这些患者被确认感染了SARS-CoV-2,被送往ICU.
- 使用考克斯比例风险回归分析28天ICU死亡率.
- 对比各种德克萨米他和甲基普雷迪尼索隆疗法与没有皮质类固醇治疗.
主要成果:
- 患者年龄与28天ICU死亡率显著相关 (RR:1.06;P<0.01).
- 每日6毫克德克萨米他的剂量显示出减少28天ICU死亡率的统计学意义趋势 (RR:0.40;P=0.05).
- 德克萨米他6mg/天和低剂量甲基普雷迪尼索隆与28天生存率 (OR:1.19) 显示出类似的关联.
结论:
- 皮质类固醇使用与严重的SARS-CoV-2感染中改善死亡结果有关.
- 皮质类固醇治疗的好处超出了德克萨米他的范围,表明了更广泛的治疗潜力.
相关概念视频
Pulmonary Tuberculosis I
243
Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
243
COPD: Management Using Bronchodilators and Corticosteroids
206
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
206
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
119
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
119
Insulin: Dosing Regimen and Adverse Effects
172
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
172
Acute Respiratory Failure-V
139
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
139
Comparing the Survival Analysis of Two or More Groups
186
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
186


